Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Study of RM-718 Weekly Formulation in Healthy Subjects With Obesity and in Patients With Obesity Due to MC4R Impairment

Next Previous
Trial Profile

A Study of RM-718 Weekly Formulation in Healthy Subjects With Obesity and in Patients With Obesity Due to MC4R Impairment

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 20 May 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs RM 718 (Primary)
  • Indications Obesity; Prader-Willi syndrome
  • Focus Adverse reactions; First in man
  • Sponsors Rhythm

Most Recent Events

  • 05 May 2026 According to a Rhythm Pharmaceuticals media release, the company plans to announce results from the Phase 1/2, Part C trial evaluating the weekly, MC4R agonist RM-718 in patients with acquired HO mid-year 2026
  • 26 Feb 2026 According to a Rhythm Pharmaceuticals media release, On December 11, 2025, the Company announced that it has initiated a Part D arm in the Phase 1/2 trial of MC4R agonist RM-718 that will enroll up to 20 patients with PWS.
  • 26 Feb 2026 According to a Rhythm Pharmaceuticals media release, the company anticipate to complete enrollment in the Phase 1/2, Part D trial evaluating RM-718 in PWS in the second half of 2026.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top